Cargando…
Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors
Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC c...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178360/ https://www.ncbi.nlm.nih.gov/pubmed/30301885 http://dx.doi.org/10.1038/s41467-018-06366-z |
_version_ | 1783361953741144064 |
---|---|
author | Gara, Sudheer Kumar Lack, Justin Zhang, Lisa Harris, Emerson Cam, Margaret Kebebew, Electron |
author_facet | Gara, Sudheer Kumar Lack, Justin Zhang, Lisa Harris, Emerson Cam, Margaret Kebebew, Electron |
author_sort | Gara, Sudheer Kumar |
collection | PubMed |
description | Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37–57% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs. |
format | Online Article Text |
id | pubmed-6178360 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-61783602018-10-11 Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors Gara, Sudheer Kumar Lack, Justin Zhang, Lisa Harris, Emerson Cam, Margaret Kebebew, Electron Nat Commun Article Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37–57% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs. Nature Publishing Group UK 2018-10-09 /pmc/articles/PMC6178360/ /pubmed/30301885 http://dx.doi.org/10.1038/s41467-018-06366-z Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Gara, Sudheer Kumar Lack, Justin Zhang, Lisa Harris, Emerson Cam, Margaret Kebebew, Electron Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors |
title | Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors |
title_full | Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors |
title_fullStr | Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors |
title_full_unstemmed | Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors |
title_short | Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors |
title_sort | metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178360/ https://www.ncbi.nlm.nih.gov/pubmed/30301885 http://dx.doi.org/10.1038/s41467-018-06366-z |
work_keys_str_mv | AT garasudheerkumar metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors AT lackjustin metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors AT zhanglisa metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors AT harrisemerson metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors AT cammargaret metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors AT kebebewelectron metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors |